The relation between excitation energy and reaction observables has been examined for protons, (5.0–9.2)-GeV and antiprotons incident on a target. Relative to proton and beams, antiprotons are found to be the most effective projectile for depositing high excitation energies in the targetlike residue. For protons and the excitation-energy distributions are nearly identical and appear to be independent of beam momentum above It is found that total measured charge, total thermal energy, and total charged-particle multiplicity scale most directly with excitation energy, whereas IMF multiplicity and total transverse energy exhibit large fluctuations. Correlations of the observed fragment multiplicity, charge, and kinetic-energy distributions with excitation energy indicate a transition in the reaction observables near These experimental signals are consistent with a multifragmentation mechanism that becomes the dominant deexcitation mode above in the range
A binomial reducibility and thermal scaling analysis is performed on well-chacracterized thermal-like sources formed in reactions. The fragment probability distributions are shown to be binomial when plotted as a function of the measured excitation energy and the binomial elementary probability p is shown to follow the expected Boltzmann factor: Binomial reducibility and thermal scaling are explored also using global variables other than and the effect of source size on the binomial parameter p and m is shown. Finally, the extracted probability p is found to be correlated with the experimentally deduced fragment emission time up to about of excitation energy, hinting at a possible transition in decay mechanism above that excitation energy.
Purpose: One major challenge facing simultaneous positron emission tomography (PET)/ magnetic resonance imaging (MRI) is PET attenuation correction (AC) measurement and evaluation of its accuracy. There is a crucial need for the evaluation of current and emergent PET AC methodologies in terms of absolute quantitative accuracy in the reconstructed PET images. Approach: To address this need, we developed and evaluated a lesion insertion tool for PET/MRI that will facilitate this evaluation process. This tool was developed for the Biograph mMR and evaluated using phantom and patient data. Contrast recovery coefficients (CRC) from the NEMA IEC phantom of synthesized lesions were compared to measurements. In addition, SUV biases of lesions inserted in human brain and pelvis images were assessed from PET images reconstructed with MRI-based AC (MRAC) and CT-based AC (CTAC). Results: For cross-comparison PET/MRI scanners AC evaluation, we demonstrated that the developed lesion insertion tool can be harmonized with the GE-SIGNA lesion insertion tool. About <3 % CRC curves difference between simulation and measurement was achieved. An average of 1.6% between harmonized simulated CRC curves obtained with mMR and SIGNA lesion insertion tools was achieved. A range of −5 % to 12% MRAC to CTAC SUV bias was respectively achieved in the vicinity and inside bone tissues in patient images in two anatomical regions, the brain, and pelvis. Conclusions: A lesion insertion tool was developed for the Biograph mMR PET/MRI scanner and harmonized with the SIGNA PET/MRI lesion insertion tool. These tools will allow for an accurate evaluation of different PET/MRI AC approaches and permit exploration of subtle attenuation correction differences across systems.
Preclinical imaging is a critical component in translational research with significant complexities in workflow and site differences in deployment. Importantly, the National Cancer Institute’s (NCI) precision medicine initiative emphasizes the use of translational co-clinical oncology models to address the biological and molecular bases of cancer prevention and treatment. The use of oncology models, such as patient-derived tumor xenografts (PDX) and genetically engineered mouse models (GEMMs), has ushered in an era of co-clinical trials by which preclinical studies can inform clinical trials and protocols, thus bridging the translational divide in cancer research. Similarly, preclinical imaging fills a translational gap as an enabling technology for translational imaging research. Unlike clinical imaging, where equipment manufacturers strive to meet standards in practice at clinical sites, standards are neither fully developed nor implemented in preclinical imaging. This fundamentally limits the collection and reporting of metadata to qualify preclinical imaging studies, thereby hindering open science and impacting the reproducibility of co-clinical imaging research. To begin to address these issues, the NCI co-clinical imaging research program (CIRP) conducted a survey to identify metadata requirements for reproducible quantitative co-clinical imaging. The enclosed consensus-based report summarizes co-clinical imaging metadata information (CIMI) to support quantitative co-clinical imaging research with broad implications for capturing co-clinical data, enabling interoperability and data sharing, as well as potentially leading to updates to the preclinical Digital Imaging and Communications in Medicine (DICOM) standard.